Company profile: LEAF Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of biotechnology and healthcare products, including investigational anticancer drugs targeting solid tumors (LEAF-1401, LEAF-1701) with preclinical results showing reduced metastatic tumor burden in lung cancer models, superior performance in colorectal models, and minimal myelosuppression and gastrointestinal toxicity, plus LEAF-1404, a complex generic anticancer medicine manufactured under global cGMP.
Products and services
- LEAF-1401: An investigational-stage anticancer drug targeting solid tumors, reducing metastatic burden in lung cancer models and outperforming in colorectal tumor models
- LEAF-1404: A cGMP-compliant complex generic anticancer medicine fabricated under global current good manufacturing practices for standardized oncology manufacturing
- LEAF-1701: A preclinical-validated investigational anticancer drug targeting solid tumors, demonstrating minimal myelosuppression and minimal gastrointestinal toxicity in preclinical studies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to LEAF Pharmaceuticals
Prismic Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel prescription medical drugs for inflammatory diseases and prescription medical foods for the clinical dietary management of metabolic processes associated with disorders common in the aging 'baby boomer' population, including central nervous system disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prismic Pharmaceuticals company profile →
Apotheca Biosciences
HQ: United States
Website
- Description: Provider of cutting-edge medical products, nutraceuticals, and formulation and delivery technologies for the healthcare and consumer care industry, including transdermal, sublingual, and nasal delivery technologies for precise, controlled dosing of cannabinoids.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apotheca Biosciences company profile →
Annovation BioPharma
HQ: United States
Website
- Description: Provider of pharmaceutical products focused on anesthesia, sedation and sleep; incorporated in 2009 and based in Wayland, Massachusetts.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Annovation BioPharma company profile →
PepGen
HQ: United Kingdom
Website
- Description: Provider of an Enhanced Delivery Oligonucleotide (EDO) platform to improve delivery and efficacy of oligonucleotide therapies, focusing on antisense oligonucleotides for neuromuscular and neurological disorders, and therapy candidates including PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) and PGN-EDO51 for Duchenne Muscular Dystrophy (DMD).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PepGen company profile →
Eton Pharmaceuticals
HQ: United States
Website
- Description: Provider of proprietary formulations of approved molecules and pharmaceutical products to fulfill unmet patient needs. Develops and commercializes a diversified pipeline of around eight candidates in various stages. Receives milestone payments and royalties on commercial sales from seven products it developed and submitted regulatory applications for to the FDA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eton Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for LEAF Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to LEAF Pharmaceuticals
2.2 - Growth funds investing in similar companies to LEAF Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for LEAF Pharmaceuticals
4.2 - Public trading comparable groups for LEAF Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →